Summary
Among 29 evaluable patients with progressive metastatic renal cell cancer treated by interferonα2b in combination with vindesine and ifosfamide, we have observed an objective (complete and partial) response rate of 24.1% and an overall (complete and partial response and stable disease) response rate of 58.6%. The median duration of remission has not yet been reached, but the survival of responding patients is considerably longer than that of non-responders. Because we could not find any differences (sex, age, WHO performance status, prior therapy, site of metastatic disease) between responding and non-responding patients, we believe that the treatment might modify intrinsic characteristics of the tumour growth and/or host-tumour relationship in the long term. Although the toxicity recorded is high, the results are sufficiently positive to justify further investigation of this approach.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aapro MS, Alberts DS, Salmon SE (1983) Interactions of human leucocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumours in colongenic assay. Cancer Chemother Pharmacol 10:161–164
Bergerat J-P, Herbrecht R, Dufour P, Jacqmin D, Bollack C, Prevot G, Bailly G, De Garis S, Juraschek F, Oberling F (1988) Combination of recombinant interferon alpha-2A and vinblastine in advanced renal cell cancer. Cancer 62:2320–2324
Buzaid AC, Todd, MB (1989) Therapeutic options in renal cell carcinoma. Semin Oncol 16 [Suppl 1]:9–12
Carmichael J, Fergusson RJ, Wolf CR, Balkwill FR, Smyth JF (1986) Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small lung cancer xenografts. Cancer Res 46:4916–4920
Figlin RA, De Kernion JB, Maldazys J, Sarna G (1985) Treatment of renal cell carcinoma with alfa (human leucocyte) interferon and vinblastine combination: a phase I–II trial. Cancer Treat Rep 69:263–267
Fossa SD, De Garis ST, Heier MS (1986) Recombinant interferon alpha 2a with or without vinblastine in metastatic renal cell carcinoma. Cancer 57:1700–1704
Harris DT (1983) Hormonal therapy and chemotherapy of renal cell carcinoma. Semin Oncol 10:422–430
Hartwich G, König HJ (1982) Combination-chemotherapy by metastatic hypernephroma with ifosfamide and vincristine. A phase II Study. Proc 13th Int Cancer Congr, Seattle, Wash., USA
Kempf RA, Grunberg SM, Daniels JR (1984) Recombinant interferon alpha 2 in a phase II study of renal cell carcinoma. Proc Am Soc Clin Oncol 3:59
König HJ, Hartwich G (1980) Zytostatische Therapie des hypernephroiden Nierenkarzinoms. Dtsch Wochenschr 106:1810–1814
Krown SE, Eizing AL, Abrahamson JD, Oettgen HF (1983) Treatment of advanced renal cell cancer with recombinant leucocyte A interferon. Proc Am Soc Clin Oncol 2:58
Muss HB (1988) The role of biological response modifiers in metastatic renal cell carcinoma. Semin Oncol 15 [Suppl 5]:4–30
Neidhardt JA (1986) Interferon therapy for the treatment of renal cancer. Cancer 57:1696–1699
Neidhardt J, Harris J, Tuttle R (1987) A randomized study of wellferon (WFN) with or without vinblastine. Presse Med 16:1953–1956
Quesada JR (1989) Role of interferons in the treatment of metastatic renal cell carcinoma. Urology 34 [Suppl 4]:80–83
Queseda JR, Swanson DA, Trindale A, Gutterman JV (1983) Renal cell carcinoma: Antitumor effects of leucocyte interferon. Cancer Res 43:940–943
Trump DL, Ravdin PM, Borden EC, Magers CF, Whisnant JK (1990) Interferon-alpha N1 and continous infusion vinblastine for treatment of advanced renal cell carcinoma. J Biol Response Mod 9:108–111
Schornagel J, Verweij J, Bokkel Huinik W ten (1987) Phase II study of recombinant interferon alpha-2 (IFN) and vinblastine (V) in advanced renal carcinoma (ARC). Proc Am Soc Clin Oncol 6:106
Weißmüller J, König HJ, Missmahl M (1983) Behandlungsergebnisse der zytostatischen Therapie beim metastasierten Nieren-Karzinom. Verh Dt Ges Urologie 34:69–71
Yagoda A, Bander NH (1989) Failure of cytotoxic chemotherapy, 1983–1988, and the emerging role of monocolonal antibodies for renal cancer. Urol Int 44:338–345
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
König, H.J., Gutmann, W. & Weissmüller, J. Ifosfamide, vindesine and recombinant α-interferon combination chemotherapy for metastatic renal cell carcinoma. J Cancer Res Clin Oncol 117 (Suppl 4), S221–S223 (1991). https://doi.org/10.1007/BF01613231
Issue Date:
DOI: https://doi.org/10.1007/BF01613231